PMCB PharmaCyte Biotech, Inc.

Overview and Growth

In fiscal 2026, PharmaCyte Biotech, Inc. recorded $0.00 of revenue, net loss of $19.42M, and an operating cash outflow of $5.15M. Diluted earnings per share were -$2.77, translating the period’s attributable earnings into the amount reported for each diluted share. The per-share result recorded a 186.8% decrease from fiscal 2025 diluted EPS of $3.19. Diluted shares averaged 8.38M; this is the reported share base over which the company’s diluted per-share earnings were spread. The diluted share count was 14.3% higher than fiscal 2025, when diluted shares averaged 7.33M, adding context to the EPS comparison. The company employed $46.75M of total assets, the balance-sheet base supporting its current operating and cash-flow results.

Profitability

The reported operating result was an operating loss of $6.85M, reflecting costs that exceeded gross profit. The bottom-line result was a net loss of $19.42M after operating, financing, tax, and other recognized items. Income tax expense totaled $0.00, providing the reported tax component that separates pretax and after-tax earnings. The loss-to-equity relationship was 55.5%, placing the bottom-line deficit against shareholder capital. The loss-to-assets relationship was 41.5%, placing the bottom-line deficit against the company’s resource base. The company moved from fiscal 2025 net income of $30.66M to a current net loss of $19.42M.

Liquidity and Capital Structure

Total assets were $46.75M, supported by $11.77M of liabilities and $34.98M of shareholder equity. The near-term balance sheet paired $37.42M of current assets with $826.42K of current liabilities at the reporting date. Current assets covered current liabilities by 45.28x, leaving a positive buffer for near-term obligations. Cash and equivalents totaled $18.60M, identifying the most liquid reported component available within the broader current-asset balance. Equity equaled 74.8% of assets, showing the shareholder-capital layer within the company’s balance sheet. The liabilities-to-assets relationship was 25.2%, placing reported obligations against the full positive asset balance. Cash and equivalents equaled 39.8% of total assets, showing the liquid cash component within the company’s broader resource base. The asset base changed 15.3% from $55.17M in fiscal 2025, leaving current total assets lower year over year. Reported equity changed 32.6% from $51.89M in fiscal 2025, placing the current capital base lower year over year. The reported cash balance changed 22.6% from $15.17M in fiscal 2025, ending higher year over year.

Cash Flow and Earnings Quality

Operating activities used $5.15M of cash, resulting in an operating cash outflow for the year. Compared with a $2.98M operating cash outflow in fiscal 2025, the current outflow increased to $5.15M.

Based on the annual report for the fiscal year ending Apr 30, 2026. Analysis generated Oct 21, 2026.